Zur Kurzanzeige

2009-07-01Zeitschriftenartikel DOI: 10.1086/599313
Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictorof AIDS‐Related Lymphoma
dc.contributor.authorZoufaly, Alexander
dc.contributor.authorStellbrink, Hans-Jürgen
dc.contributor.authorHeiden, Matthias an der
dc.contributor.authorKollan, Christian
dc.contributor.authorHoffmann, Christian
dc.contributor.authorLunzen, Jan van
dc.contributor.authorHamouda, Osamah
dc.date.accessioned2018-05-07T14:01:23Z
dc.date.available2018-05-07T14:01:23Z
dc.date.created2010-07-02
dc.date.issued2009-07-01none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/reptYWi13tDKk/PDF/223SAOkwBZS2k.pdf
dc.identifier.urihttp://edoc.rki.de/176904/687
dc.description.abstractBackground.AIDS‐related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)–infected patients receiving highly active antiretroviral therapy (HAART). We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS‐related non‐Hodgkin lymphoma. Methods.Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational, open cohort study of HIV‐infected patients from different urban areas in Germany, were analyzed using a Cox proportional hazards model. Results.In the Cox model, which comprised 6022 patients and 27,812 patient‐years of follow‐up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27–2.20]) (P < ,001 ). This association differed markedly between lymphoma subtypes. Although the association was more pronounced for Burkitt‐type lymphoma (HR, 3.45 [95% CI, 1.52–7.85]) ( P = ,003 ), there was no association between cumulative HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39–2.57]) (P = ,997 ). Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4 T cell count as well as age per 10‐year increment. Conclusions.Cumulative HIV viremia is an independent and strong predictor of AIDS‐related lymphoma among patients receiving HAART. The influence of cumulative HIV viremia may differ between lymphoma subtypes.eng
dc.language.isoeng
dc.publisherRobert Koch-Institut
dc.subjectHumanseng
dc.subjectFemaleeng
dc.subjectGermany/epidemiologyeng
dc.subjectMaleeng
dc.subjectRisk Factorseng
dc.subjectCohort Studieseng
dc.subjectViral Loadeng
dc.subjectCD4 Lymphocyte Counteng
dc.subjectAntiretroviral Therapyeng
dc.subjectHighly Activeeng
dc.subjectHIV Infections/complicationseng
dc.subjectHIV Infections/drug therapyeng
dc.subjectLymphomaeng
dc.subjectAIDS-Related/epidemiologyeng
dc.subjectAIDS-Related/mortalityeng
dc.subjectProportional Hazards Modelseng
dc.subjectSurvival Analysiseng
dc.subjectViremia/complicationseng
dc.subjectViremia/drug therapyeng
dc.subjectViremia/epidemiologyeng
dc.subject.ddc610 Medizin
dc.titleCumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictorof AIDS‐Related Lymphoma
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-1009549
dc.identifier.doi10.1086/599313
dc.identifier.doihttp://dx.doi.org/10.25646/612
local.edoc.container-titleJournal of Infectious Diseases
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://www.journals.uchicago.edu/doi/abs/10.1086/599313?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov
local.edoc.container-publisher-nameUniversity of Chicago Press
local.edoc.container-volume200
local.edoc.container-year2009

Zur Kurzanzeige